Furthermore, ovarian cancer patients harbouring deletions of either CDK12 or CDK13 also carry mutations in at least one other DDR gene, supporting the idea that loss of CDK12/13 is associated with higher tumour mutation burden [59]. This evidence concerns the gene CDK13 and neoplasm.